FIGURE 6 from Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy

Impact of AZA treatment on mutant cell populations in responder patients. A, Mutant cell type proportions at diagnosis and after AZA treatment in responders. *, scCODA FDR <0.1. B, UMAPs at diagnosis and after AZA in all the HMA responder patients, colored by number of mutations per cell, highlight the three mutant populations significantly associated with response. C, UMAPs highlighting mutant HSPCs in patient #2 (responder), mutant immature granulocytes in patient #9 (responder) and mutant immature monocytes in patient #7 (responder), colored by clone. Dx, diagnosis; Aza, after AZA treatment.